Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ostin Technology Group Co., Ltd. designs, develops, and manufactures thin-film transistor liquid crystal display (TFT-LCD) modules and polarizers in China. The company offers TFT-LCD solutions for drive IC, TCON board, and power supply applications; back light systems and special modules; LC display modules, touch panel modules, and smart display terminals; and polarizers used in the TFT-LCD display modules. It offers display modules to markets, such as consumer electronics, including AIOs, monitors, laptop computers, and tablets; automotive displays, including dashboard, and navigation and multimedia systems; and outdoor LCD displays, which are used to display multimedia graphics, such as company advertisements, promotions, scoreboards, and traffic signs. The company sells its products directly to customers, as well as to customers' designated system integrators. Ostin Technology Group Co., Ltd. was founded in 2010 and is based in Nanjing, China with manufacturing facilities in China.

Ostin Technology Group Co., Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FDA CONFIRMED THAT DATA FROM SINGLE-ARM STUDIES IN RARE DISEASES, SUCH AS IN ULTRA-RARE DEADLY PEDIATRIC CANCER OSTEOSARCOMA, COULD SUPPORT A BIOLOGICS LICENSING APPLICATION (BLA) UNDER ACCELERATED APPROVAL PROGRAM PATHWAY, AS STATED IN FDA GUIDANCE DOCUMENTS FDA PROPOSED CONFIRMATORY STUDY DESIGN INCLUDE ADDITIONAL OSTEOSARCOMA DISEASE SETTINGS SUCH AS PREVENTION OF RECURRENCE FOLLOWING PRIMARY TUMOR RESECTION, WHERE A RANDOMIZED CONTROLLED STUDY MAY BE FEASIBLE AND THAT THE CONFIRMATORY STUDY WOULD HAVE TO BE UNDERWAY PRIOR TO GRANTING A BLA FDA INDICATED THAT THE USE OF CANINE DATA TO SUPPORT CONFIRMATION THAT PRE-SPECIFIED IMMUNE BIOMARKER ACTIVATION IS CORRELATED WITH TREATMENT-EMERGENT HUMAN CLINICAL BENEFIT WILL DEPEND ON BIOMARKERS CHOSEN FOR EVALUATION & CLINICAL VALIDATION THEREOF FDA REQUESTED FOLLOW-UP MEETING ONCE IMMUNE ACTIVATION BIOMARKER ANALYSIS IS AVAILABLE TO REVIEW DATA WITHIN CONTEXT OF PENDING COMPANY-PLANNED BLA FILING KEY OPINION LEADER DR. PETER ANDERSON, WHO PARTICIPATED IN THE MEETING FOLLOWING FDA'S REQUEST THAT A KEY OPINION LEADER BE PRESENT TO HELP EDUCATE THE AGENCY ON THE STANDARD OF CARE IN OSTEOSARCOMA, NOTED THAT IMMUNOTHERAPIES SUCH AS OST-HER2 ARE THE MOST PROMISING TREATMENT CATEGORY BEING INVESTIGATED COMPANY ANTICIPATES IMMUNE ACTIVATION BIOMARKER ANALYSIS DATA WILL BE RELEASED DURING WEEK OF THE JP MORGAN HEALTHCARE CONFERENCE IN JANUARY 2026 COMPANY REITERATES END OF JANUARY 2026 TIMELINE FOR PLANNED BLA SUBMISSION, WITH FDA-PROPOSED MEETINGS TO REVIEW BIOMARKER DATA & ADDITIONAL CLINICAL DATA, AS WELL AS FINAL CONFIRMATORY STUDY DESIGN, EXPECTED TO OCCUR AFTER BLA FILING FDA FEEDBACK RECEIVED REMAINS IN ALIGNMENT WITH THE COMPANY'S INTERNATIONAL REGULATORY STRATEGY - INCLUDING THE UNITED KINGDOM AND EUROPEAN UNION NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 15, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), THE WORLD LEADER IN LISTERIA-BASED CANCER IMMUNOTHERAPIES, TODAY ANNOUNCED TH

OS THERAPIES ANNOUNCES SUCCESSFUL TYPE C MEETING WITH US FDA REGARDING PHASE 2B CLINICAL TRIAL OF OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA

ALIGNMENT ACHIEVED ON ALL KEY POINTS SURROUNDING NON-CLINICAL, CMC AND POST-MARKET AUTHORIZATION CONFIRMATORY STUDY DESIGN BIOMARKER DATA ADVANCED AS KEY PRE-SPECIFIED SURROGATE CLINICAL EFFICACY ENDPOINT, WITH PENDING ANALYSIS AWAITING ALIGNMENT WITH US FDA ON BIOMARKER STATISTICAL ANALYSIS PLAN TO BE DISCUSSED AT UPCOMING DECEMBER 11, 2025 FDA TYPE C MEETING COMPANY REITERATES END OF JANUARY 2026 TIMELINE FOR MAA SUBMISSION NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 9, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), THE WORLD LEADER IN LISTERIA-BASED CANCER IMMUNOTHERAPIES, TODAY ANNOUNCED THAT IT HELD A SUCCESSFUL PRE-MARKETING AUTHORISATION APPLICATION (MAA) WITH THE UNITED KINGDOM (UK) MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) REGARDING THE PHASE 2B HUMAN CLINICAL TRIAL OF OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENT, FULLY-RESECTED, PULMONARY METASTATIC OSTEOSARCOMA (THE 'METASTATIC OSTEOSARCOMA PROGRAM'). THE COMPANY ACHIEVED FULL ALIGNMENT WITH ITS PRE-MEETING OBJECTIVES RELATED TO NON-CLINICAL, CMC (CHEMISTRY, MANUFACTURING, AND CONTROLS) AND POST-MARKET AUTHORIZATION CONFIRMATORY STUDY DESIGN.

OS THERAPIES ANNOUNCES SUCCESSFUL PRE-MARKETING AUTHORISATION APPLICATION MEETING WITH UK MHRA REGARDING THE PHASE 2B CLINICAL TRIAL OF OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA

U.S. FDA GRANTS WAIVER OF APPLICATION FEE FOR BLA FILING OF OST-HER2 SCHEDULED PRE-MARKETING AUTHORISATION APPLICATION MEETING WITH UNITED KINGDOM'S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY ON DECEMBER 8, 2025 SCHEDULED TYPE C MEETING WITH UNITED STATES FOOD & DRUG ADMINISTRATION ON DECEMBER 11, 2025 NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 5, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), THE WORLD LEADER IN LISTERIA-BASED CANCER IMMUNOTHERAPIES, TODAY ANNOUNCED THE UNITED STATES FOOD & DRUG ADMINISTRATION (FDA) GRANTED THE COMPANY WAIVER OF THE APPLICATION FEE FOR BLA 125867 FOR OST-HER2. ADDITIONALLY, THE EUROPEAN MEDICINES AGENCY (EMA) COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ('CHMP') GRANTED UNION MARKETING AUTHORISATION ELIGIBILITY FOR OST-HERS IN THE PREVENTION OR DELAY OF RECURRENT, FULLY-RESECTED, PULMONARY METASTATIC OSTEOSARCOMA (THE 'METASTATIC OSTEOSARCOMA PROGRAM').

OS THERAPIES ANNOUNCES FDA PDUFA WAIVER & EMA GRANTS UNION MARKETING AUTHORISATION ELIGIBILITY

NEW YORK, NEW YORK--(NEWSFILE CORP. - NOVEMBER 25, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), THE WORLD LEADER IN LISTERIA-BASED CANCER IMMUNOTHERAPIES, TODAY ANNOUNCED THAT THE INTERNATIONAL NONPROPRIETARY NAMES (INN) EXPERT COMMITTEE OF THE WORLD HEALTH ORGANIZATION (WHO) APPROVED 'DAZNELIMGENE LISBAC' FOR THE NON-PROPRIETARY NAME FOR THE COMPANY'S HER2 TARGETED LISTERIA MONOCYTOGENES-BASED CANCER IMMUNOTHERAPY PRODUCT CANDIDATE OST-HER2. OST-HER2 IS CURRENTLY BEING DEVELOPED FOR THE PREVENTION OR DELAY OF RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA.

OS THERAPIES RECEIVES NON-PROPRIETARY NAME 'DAZNELIMGENE LISBAC' FOR OST-HER2 FROM WORLD HEALTH ORGANIZATION

NEW YORK, NEW YORK--(NEWSFILE CORP. - OCTOBER 22, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), A CLINICAL-STAGE CANCER IMMUNOTHERAPY AND ANTIBODY DRUG CONJUGATE BIOTECHNOLOGY COMPANY, TODAY ANNOUNCED ADDITIONAL OVERALL AND EVENT FREE SURVIVAL DATA GENERATED FROM THE COMPANY'S 41-PATIENT PHASE 2B CLINICAL TRIAL OF ITS OFF-THE-SHELF IMMUNOTHERAPEUTIC CANDIDATE OST-HER2 IN RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA (THE "PHASE 2B OSTEOSARCOMA TRIAL"). THE COMPANY PREVIOUSLY ANNOUNCED STATISTICALLY SIGNIFICANT POSITIVE FINAL 2-YEAR OVERALL SURVIVAL DATA FROM ITS PHASE 2B OSTEOSARCOMA TRIAL ON OCTOBER 10, 2025.

OS THERAPIES ANNOUNCES OVERALL AND EVENT FREE SURVIVAL KEY SUBGROUP DATA FOR OST-HER2 IN RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA

75% OF OST-HER2 TREATED PATIENTS ACHIEVED 2-YEAR OVERALL SURVIVAL COMPARED WITH 40% IN THE HISTORICAL CONTROL GROUP (P < 0.0001) 100% OF PATIENTS WHO ACHIEVED 12 MONTH EVENT FREE SURVIVAL ACHIEVED 2 YEAR OVERALL SURVIVAL NEW YORK, NEW YORK--(NEWSFILE CORP. - OCTOBER 10, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), A CLINICAL-STAGE CANCER IMMUNOTHERAPY AND ANTIBODY DRUG CONJUGATE BIOTECHNOLOGY COMPANY, TODAY ANNOUNCED STATISTICALLY SIGNIFICANT POSITIVE FINAL 2-YEAR OVERALL SURVIVAL DATA FROM THE COMPANY'S PHASE 2B TRIAL OF OFF-THE-SHELF IMMUNOTHERAPY CANDIDATE OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENT, FULLY-RESECTED, PULMONARY METASTATIC OSTEOSARCOMA (THE "FULLY RESECTED METASTATIC OSTEOSARCOMA TRIAL"). 75% (27 OUT OF 36 EVALUABLE PATIENTS; 5 PATIENTS WERE LOST TO FOLLOW-UP) OF OST-HER2 TREATED PATIENTS ACHIEVED 2-YEAR OVERALL SURVIVAL AS MEASURED FROM MOST RECENT PULMONARY RESECTION, COMPARED WITH 40% OF HISTORICAL CONTROL PATIENTS1 (P < 0.0001) SUBGROUP ANALYSES SHOWED THAT 100% OF PATIENTS WHO ACHIEVED 12-MONTH EVENT FREE SURVIVAL (EFS) ACHIEVED 2-YEAR OVERALL SURVIVAL, WHEREAS 59% OF PATIENTS WHO DID NOT ACHIEVE EFS ACHIEVED 2-YEAR OVERALL SURVIVAL.

OS THERAPIES ANNOUNCES STATISTICALLY SIGNIFICANT POSITIVE FINAL 2-YEAR OVERALL SURVIVAL DATA FROM PHASE 2B TRIAL OF OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENT, FULLY-RESECTED, PULMONARY METASTATIC OSTEOSARCOMA

COMPANY UPDATES SEQUENCE OF OST-HER2 REGULATORY SUBMISSIONS, PRIORITIZING UK MHRA CONDITIONAL MARKETING AUTHORISATION APPLICATION (MAA) SUBMISSION FOLLOWING POSITIVE AUGUST 2025 SCIENTIFIC ADVICE MEETING FEEDBACK FROM UK MHRA IN PRINCIPLE, UK MHRA ACCEPTS USE OF HISTORICAL CONTROL ARM TO SUPPORT CONDITIONAL MAA UK MHRA CONDITIONAL MAA AND US FDA BIOLOGICS LICENSING APPLICATION (BLA) SUBMISSIONS EXPECTED TO BE COMPLETED WITHIN 30 DAYS OF EACH OTHER, BETWEEN DECEMBER 2025 AND JANUARY 2026 COMPANY TO PROPOSE USE OF IMMUNE ACTIVATION BIOMARKER COUPLED WITH OVERALL SURVIVAL DATA AS SURROGATE EFFICACY ENDPOINT TO SUPPORT ACCELERATED APPROVAL IN TYPE C MEETING INVITED BY FDA, FOLLOWING POSITIVE END OF PHASE 2 MEETING AND FOLLOW-UP INTERACTIONS NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 30, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), A CLINICAL-STAGE CANCER IMMUNOTHERAPY AND ANTIBODY DRUG CONJUGATE BIOTECHNOLOGY COMPANY, TODAY PROVIDED A REGULATORY UPDATE ON ITS PLANS FOR FILING MARKETING AUTHORIZATIONS IN THE UNITED STATES (US) AND UNITED KINGDOM (UK) FOR OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA BASED ON A DATA GENERATED FROM ITS COMPLETED PHASE 2B CLINICAL TRIAL CURRENTLY IN THE LONG TERM FOLLOW-UP PHASE. THE COMPANY HAS UPDATED ITS REGULATORY FILING SEQUENCE TO PRIORITIZE THE UK MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) CONDITIONAL MARKETING AUTHORISATION APPLICATION (MAA) FINAL MODULE SUBMISSION TO IMMEDIATELY PRECEDE ITS US FDA BIOLOGICS LICENSING APPLICATION (BLA) FINAL MODULE SUBMISSION UNDER THE ACCELERATED APPROVAL PROGRAM (ACCELERATED APPROVAL).

OS THERAPIES PROVIDES OST-HER2 UK MHRA AND US FDA OSTEOSARCOMA REGULATORY UPDATE

CLINICAL DATA FROM PHASE 1B PROSTATE CANCER TRIAL TO BE RELEASED IN Q4/25 ADDITIONALLY, UPDATED 2-YEAR OVERALL SURVIVAL DATA FROM ALL 40 PATIENTS IN THE PHASE 2B CLINICAL TRIAL OF OST-HER2 IN THE PREVENTION OF DELAY OF RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA TO BE RELEASED ON OCTOBER 10, 2025 NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 12, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), A CLINICAL-STAGE CANCER IMMUNOTHERAPY AND ANTIBODY DRUG CONJUGATE BIOTECHNOLOGY COMPANY, TODAY ANNOUNCED THAT THE LAST PATIENT ENROLLED IN ITS OST-504 (PREVIOUSLY ADXS-504) PHASE 1B CLINICAL TRIAL IN SUBJECTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER PREVIOUSLY TREATED WITH RADICAL PROSTATECTOMY (RP) OR RADIATION THERAPY (EXTERNAL BEAM OR BRACHYTHERAPY) WHO ARE NOT CURRENTLY RECEIVING ANDROGEN ABLATION THERAPY HAS COMPLETED THEIR LAST PATIENT VISIT (NCT05077098). A TOTAL OF 7 PATIENTS ENROLLED IN THE STUDY.

OS THERAPIES ANNOUNCES LAST PATIENT ENROLLED IN OST-504 (PREVIOUSLY ADXS-504) PHASE 1B PROSTATE CANCER CLINICAL TRIAL COMPLETES LAST VISIT

COMPANY ON TRACK TO BEGIN SUBMISSION OF A ROLLING BIOLOGICS LICENSING APPLICATION (BLA) REQUEST FOR OST-HER2 TO U.S. FOOD & DRUG ADMINISTRATION IN SEPTEMBER 2025 NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 2, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), A CLINICAL-STAGE CANCER IMMUNOTHERAPY AND ANTIBODY DRUG CONJUGATE BIOTECHNOLOGY COMPANY, TODAY PROVIDED STAKEHOLDERS WITH A DETAILED UPDATE REGARDING THE COMPANY'S OST-HER2 RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA PROGRAM (THE "METASTATIC OSTEOSARCOMA PROGRAM") FOLLOWING A HIGHLY PRODUCTIVE END OF PHASE 2 MEETING WITH THE US FOOD & DRUG ADMINISTRATION ("FDA"). THE COMPANY REMAINS ON TRACK TO BEGIN ROLLING SUBMISSION OF A BIOLOGICS LICENSING APPLICATION ("BLA") REQUEST TO FDA FOR THE METASTATIC OSTEOSARCOMA PROGRAM IN SEPTEMBER 2025.

OS THERAPIES PROVIDES OST-HER2 RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA PROGRAM UPDATE FOLLOWING FDA END OF PHASE 2 MEETING

NEW YORK, NEW YORK--(NEWSFILE CORP. - AUGUST 27, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), A CLINICAL-STAGE CANCER IMMUNOTHERAPY AND ANTIBODY DRUG CONJUGATE BIOTECHNOLOGY COMPANY, TODAY ANNOUNCED THAT IT WILL PROVIDE STAKEHOLDERS WITH A DETAILED UPDATE REGARDING THE COMPANY'S HIGHLY CONSTRUCTIVE AUGUST 27, 2025 END OF PHASE 2 MEETING WITH THE US FOOD & DRUG ADMINISTRATION ("FDA") DISCUSSING THE REGULATORY PATH FORWARD TOWARDS APPROVAL FOR OST-HER2 IN RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA ON TUESDAY, SEPTEMBER 2, 2025. ABOUT OS THERAPIES OS THERAPIES IS A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON THE IDENTIFICATION, DEVELOPMENT, AND COMMERCIALIZATION OF TREATMENTS FOR OSTEOSARCOMA (OS) AND OTHER SOLID TUMORS.

OS THERAPIES TO PROVIDE OST-HER2 RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA FDA END OF PHASE 2 MEETING UPDATE ON TUESDAY, SEPTEMBER 2, 2025

Ostin Technology Group Co., Ltd.

OST

Price

Financial Reports

No items found.

Press Releases

Ostin Technology Group Co., Ltd.

OST.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

OST